The Business Research Company’s report on the Lupus Nephritis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the lupus nephritis market further?
The increasing prevalence of genetic predisposition is expected to propel the growth of the lupus nephritis market going forward. Genetic predisposition refers to an individual’s inherited genetic traits that increase their likelihood of developing certain diseases or conditions. The increasing prevalence of genetic predisposition is due to factors such as inheritance, environmental influences, and mutations in specific genes. The increasing prevalence of genetic predisposition plays a significant role in the development of lupus nephritis, emphasizing the impact of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry recorded 11,148 registered patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% increase in individuals with cystic fibrosis (CF). Therefore, the increasing prevalence of genetic predisposition is driving the growth of the lupus nephritis market.
Access Your Free Sample of the Global Lupus Nephritis Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp
What are the key factors influencing the forecasted market size of the lupus nephritis industry?
The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing research investments in lupus nephritis, rising incidence of autoimmune diseases, rising healthcare expenditure, growing adoption of biologics, and growing popularity of telemedicine.
The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.80 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the rise in physician awareness, increasing adoption of biologic therapies, increasing number of specialty clinics, increasing importance of renal transplantation, and increasing access to nephrology services. Major trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, novel diagnostic biomarkers, expansion of clinical trials, and advancements in stem cell therapy.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp
Who are the leading competitors in the lupus nephritis market?
Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.
Which emerging trends are set to transform the lupus nephritis market landscape?
Major companies operating in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to enhance treatment efficacy and improve long-term kidney outcomes for patients. Second-generation calcineurin inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on data from the AURORA Clinical Program, which demonstrated its safety and efficacy. The approval marks a significant milestone in expanding treatment options for lupus nephritis patients in Japan, improving disease management and outcomes.
How do different geographies compare in terms of market share and growth potential in the lupus nephritis market?
Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report
Which major segments of the lupus nephritis market are experiencing the fastest growth?
The lupus nephritis market covered in this report is segmented –
1) By Stage: Class 1, Class 2, Class 3, Other Stages
2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs
3) Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis.
2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22044
How is the lupus nephritis market defined?
Lupus nephritis is a serious kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissues, including the kidneys. This inflammation can lead to kidney damage, impaired function, and, if left untreated, potentially kidney failure, making early diagnosis and treatment crucial for managing the disease.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
